E31.22
Multiple endocrine neoplasia [MEN] type IIA
Clinical Classification Guidelines
Inclusion Terms
- Sipple's syndrome
Medical Intelligence & Overview
Multiple Endocrine Neoplasia (MEN) type IIA, also known as Sipple's syndrome, is a hereditary condition characterized by the development of tumors in multiple endocrine glands. These tumors can be benign or malignant and often lead to overproduction of hormones, causing various health issues. MEN IIA typically involves tumors in the thyroid gland, parathyroid glands, and adrenal glands, and may have implications for other parts of the endocrine system.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations, primarily involving the RET proto-oncogene Family history of MEN IIA or related endocrine tumors Autosomal dominant inheritance pattern, meaning only one copy of the mutated gene is enough to increase risk
Key Symptoms: Medullary thyroid carcinoma (a type of thyroid cancer): lump in the neck, difficulty swallowing, hoarseness Hyperparathyroidism: elevated calcium levels, kidney stones, abdominal pain, fatigue Pheochromocytoma (adrenal gland tumor): high blood pressure, headaches, sweating, rapid heartbeat Possible skin tumors or mucosal neuromas in some patients Other endocrine abnormalities, depending on tumor location and hormones involved
Diagnostic & Treatment
Diagnosis Path: Diagnosis of MEN IIA involves a combination of clinical evaluation, family history assessment, and laboratory and imaging studies. Tests may include hormone level measurements, genetic testing for RET mutations, ultrasound, nuclear scans, and biopsy procedures to identify tumors. Regular screening is essential for early detection and management of associated endocrine tumors.
Treatment Protocols: Treatment strategies focus on managing and removing tumors to prevent complications. They may include surgical removal of thyroid, parathyroid, or adrenal tumors. Pharmacologic therapy, such as hormone suppression or control of blood pressure, may be used as adjuncts. Genetic counseling is recommended for affected families to understand inheritance risks and screening options. Lifelong monitoring is critical due to the hereditary nature and potential for multiple tumors.
Clinical Advice & FAQs
Billing Guidance
Is E31.22 a billable ICD-10 code?
Yes, E31.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E31.22?
Clinical documentation must specify the nature of Multiple endocrine neoplasia [MEN] type IIA and any associated comorbidities for accurate reporting.
Cite this Clinical Reference